Dermatology · Omaha area, NE
Dermatology and skin studies in Omaha area, NE
13 recruiting studies have a site in the Omaha area. This page includes nearby cities such as Bellevue, Papillion, Elkhorn, Lincoln.
13 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
AbbVie
- Location
- Omaha, NE + 8 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics
- Location
- Omaha, NE + 18 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
AbbVie
- Location
- Omaha, NE + 29 other US sites
- Eligibility basics
- Ages 12–63
- RecruitingPhase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
Sanofi
- Location
- Bellevue, NE + 17 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Pfizer
- Location
- Omaha, NE + 18 other US sites
- Eligibility basics
- Ages 6–14
- RecruitingPhase 2
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Novartis Pharmaceuticals
- Location
- Omaha, NE + 23 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Novartis Pharmaceuticals
- Location
- Omaha, NE + 20 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 2
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
Oruka Therapeutics, Inc.
- Location
- Omaha, NE + 13 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Incyte Corporation
- Location
- Omaha, NE + 65 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 2
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
Beijing InnoCare Pharma Tech Co., Ltd.
- Location
- Omaha, NE + 13 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Eli Lilly and Company
- Location
- Omaha, NE + 28 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
A Study of LAD603 in Adults With Alopecia Areata
Almirall, S.A.
- Location
- Omaha, NE
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Sun Pharmaceutical Industries, Inc.
- Location
- Omaha, NE + 53 other US sites
- Eligibility basics
- Ages 12–17
Who these studies look for
Most require an active, diagnosed skin condition of a certain severity and a pause on some current treatments before starting.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.